Stay in the know
Discover the latest financial news and exclusive features from Laidlaw
Laidlaw Venture Partners Continues Strategic Growth with Addition of Jeff Conroy and George Serafin to its Board of Advisors
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeff Conroy and George Serafin to its Board of Advisors. As industry leaders in Business Development and Regulatory/Compliance...
Laidlaw served as Co-Manager on the $50,000,000 Follow-On Offering for Soleno Therapeutics (SLNO) with Guggenheim Partners
Laidlaw is pleased to have Co-Managed a $50,000,000 deal for Soleno Therapeutics (SLNO) with Guggenheim Partners. View Press Release
Laidlaw Venture Partners Adds Industry Leading CEOs Jeffrey O’Donnell and Dr. Ann Marie Sastry to its Board of Advisors
Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced the addition of Jeffrey O'Donnell and Dr. Ann Marie Sastry to its Board of Advisors. With more than 50 years of combined experience in leading companies across medical devices and artificial intelligence (AI) technology, O'Donnell and Sastry will help guide Laidlaw Venture Partners in building and expanding its already diverse portfolio of innovative companies.
Laidlaw served as Sole Book-Runner on the $5mm Follow-On Offering for Hoth Therapeutics (HOTH)
Laidlaw Capital Markets is pleased to announce yesterday's pricing of a $5,000,000 Follow-On Offering for Hoth Therapeutics (HOTH). Laidlaw proudly served as the Sole Book Runner on the transaction. See Press Release [...]
Laidlaw served as Introducing Broker on the $10.8mm financing for Biosig Technologies (BSGM), through its subsidiary ViralClear.
Laidlaw Venture Partners client Biosig Technologies (BSGM) through its newly formed subsidiary ViralClear, closes $10,800,000 financing. Laidlaw is proud to have acted as am Introducing Broker on this financing. See Press Release [...]
Laidlaw served as Co-Lead Manager on the $22mm financing and uplisting for Delcath Systems (DCTH)
Laidlaw Capital Markets is pleased to have acted as Co-Lead Manager on Delcath Systems' (DCTH) $22,000,000 financing and uplisting to NASDAQ. Laidlaw proudly served as the Sole Book Runner on the transaction.See Press Release [...]
Current Thoughts On The Market with S&P500 Down -16% Versus Wed 2/19 High
Apart from the fact that 26mm Americans are filing for unemployment benefits, things are not that bad from a market perspective. Thanks to the massive and relatively rapid monetary and fiscal policy response, COVID has not taken the S&P 500 down as much as the 2008 Financial Crisis did. At this point in the 2008 experience (start the sequence with 9/29/08, the first -5% move for the S&P), the index was down -17.6%. Now, (start with 3/9/20, the first -5% “crash” day), the S&P 500 is actually up +3.3%. So, based on the valuation for U.S. large cap stocks, this indicates a market view that the worst outcomes are off the table.
Laidlaw served as Financial Advisor on the $70mm Follow-On Offering for Arcturus Therapeutics (ARCT).
Laidlaw Capital Markets is pleased to announce today's pricing of a $70,000,000 Follow-On Offering for Arcturus Therapeutics (ARCT) around its Covid-19 vaccine and platform for other diseases. Laidlaw proudly served as Financial Advisor alongside Guggenheim, [...]
COVID-19 Letter